Skip to main content
Premium Trial:

Request an Annual Quote

Multiplicom Gets CE-IVD Mark for Clarigo NIPT

NEW YORK (GenomeWeb)—Multiplicom announced today that it has received CE-IVD marking for its new non-invasive prenatal test Clarigo and has launched the test in countries that recognize the designation.

Clarigo makes use of Multiplicom’s proprietary Multiplex PCR technology and performs targeted, massively parallel sequencing (MPS) for analyzing cfDNA. The Belgian firm said that fetal DNA can be analyzed in the mother's blood as early as eight weeks into the pregnancy, and Clarigo is designed to detect the presence or absence of major chromosomal abnormalities in the fetus, such as trisomy 21 (Down's syndrome), 18 (Edwards' syndrome), and 13 (Patau syndrome).

The increased sensitivity and reliability of the test provides far fewer false-positive results compared to present combined testing, sparing a large number of pregnant women from invasive procedures, Multiplicom said in a statement. However, if the test finds more than two copies of chromosome 21, 18, or 13 in the fetus, the pregnant woman will be referred to classic invasive procedures to confirm the result.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more